P-Glycoprotein (P-gp) Substrates: Clinical Overview
P-glycoprotein (P-gp) substrates are drugs that are actively transported and expelled from cells by the P-gp efflux pump, a membrane-bound protein that critically affects drug absorption in the intestine, distribution to protected sites (brain, tumors), and elimination through the kidneys and liver 1, 2.
What P-gp Does
P-gp functions as a protective "bouncer" at critical body barriers:
- Intestinal lining: Pumps drugs back into the gut lumen after absorption, reducing oral bioavailability
- Blood-brain barrier: Prevents drug entry into the central nervous system
- Kidney tubules: Actively secretes drugs into urine
- Liver canaliculi: Excretes drugs into bile
- Placenta: Protects the fetus from xenobiotics 2, 3
This ATP-dependent efflux mechanism means that P-gp substrates face active opposition to reaching therapeutic concentrations at their target sites 4.
Clinically Important P-gp Substrates
The most clinically relevant P-gp substrates in cardiovascular medicine are the direct oral anticoagulants (DOACs):
- Dabigatran: ~80% renally eliminated, most vulnerable to P-gp interactions 1
- Apixaban: 25% hepatically metabolized via CYP3A4, also P-gp substrate 1
- Rivaroxaban: 51% metabolized, dual CYP3A4/P-gp substrate 1
- Edoxaban: Minimally metabolized, primarily P-gp dependent 1, 2
Other important P-gp substrates include digoxin (the classic example with narrow therapeutic index), certain antiarrhythmics, and immunosuppressants 3, 5.
Clinical Significance: Drug-Drug Interactions
Strong P-gp Inhibitors
When a P-gp inhibitor is coadministered, substrate drug levels can more than double (>2-fold AUC increase) 1. Common P-gp inhibitors in cardiology include:
Critical interaction example: Ketoconazole more than doubles dabigatran plasma concentrations. In patients with renal impairment (CrCl <50 mL/min), this combination likely triples the AUC and should be avoided entirely 1.
Strong P-gp Inducers
P-gp inducers decrease substrate drug levels by >50%, potentially causing therapeutic failure 1. Key inducers include:
- Rifampicin
- Carbamazepine
- St. John's Wort
- Phenytoin 2
These combinations should be avoided with DOACs, as they have been associated with recurrent thromboembolism due to subtherapeutic anticoagulation 1.
Practical Management Algorithm
For dual CYP3A4 and P-gp substrates (apixaban, rivaroxaban):
For dabigatran (P-gp only):
- Strong P-gp inhibitors with CrCl <50 mL/min: contraindicated
- Strong P-gp inhibitors with normal renal function: reduce dabigatran dose or separate administration by 2 hours 1
- Moderate P-gp inhibitors (amiodarone, dronedarone, verapamil): only 10-23% AUC increase, can stagger dosing by 2 hours 1
For edoxaban:
- Only one trial (ENGAGE-AF) prospectively reduced dose with P-gp inhibitors (verapamil, quinidine, dronedarone)
- Some experts recommend switching to warfarin rather than dose reduction, especially with renal impairment 1
Common Pitfalls
The renal impairment trap: P-gp inhibition becomes exponentially more dangerous in kidney dysfunction because both mechanisms (reduced P-gp secretion + reduced glomerular filtration) compound to dramatically increase drug exposure 1. Always check creatinine clearance before combining P-gp inhibitors with substrates.
The timing solution: For moderate P-gp inhibitors, administering the inhibitor 2 hours after the P-gp substrate can substantially mitigate the interaction (e.g., ticagrelor with dabigatran: 65% peak increase when given together vs. only 24% when staggered) 1.
Dual mechanism drugs: Rivaroxaban and apixaban are both CYP3A4 and P-gp substrates, so interactions are more pronounced and clinically significant with dual inhibitors/inducers 1.